Efficacy News and Research

RSS

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Study: Transcendental meditation reduces posttraumatic stress in African refugees

A significant percentage of veterans returning from wars exhibit symptoms of posttraumatic stress (PTS). This is now recognized as a serious health problem, but what about the victims of such violence? Refugees live with the constant reminder of what war has done to their lives and those of their families.

9 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Study: Chicken-killing virus is a promising treatment for prostate cancer

A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.

9 Apr 2013

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies.

9 Apr 2013

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans.

9 Apr 2013

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

9 Apr 2013

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.

9 Apr 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.

8 Apr 2013

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

MentisCura launches clinical center for early detection of Alzheimer's disease, dementia

MentisCura Diagnostics today announced the launch of its first clinical center for the early detection of Alzheimer's disease and other dementias.

8 Apr 2013

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.

8 Apr 2013

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs.

8 Apr 2013

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress, April 4-6, Monte Carlo, Monaco.

8 Apr 2013

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C.

8 Apr 2013

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

A Spectrum Health clinical trial has found that fecal microbial transplantation (FMT) has resulted in the improvement or absence of symptoms in most pediatric patients with active ulcerative colitis.

7 Apr 2013

Efficacy News and Research

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Study: Transcendental meditation reduces posttraumatic stress in African refugees

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Study: Chicken-killing virus is a promising treatment for prostate cancer

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Study evaluates efficacy of drug combinations in treating colorectal cancer

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

GenSight Biologics announces closing of €32 million Series A financing

MentisCura launches clinical center for early detection of Alzheimer's disease, dementia

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News